CONMED stock has delivered a 59.6% decline over the past 5 years, yet on current metrics it screens as undervalued. This sets up a debate between a weak long term share price record and a more supportive current valuation read.

• The 59.6% share price decline over 5 years means long term holders have experienced a substantial loss, so any valuation case now has to compensate investors for that track record.
• Future returns can be influenced by how consistently CONMED converts revenue into cash and manages its balance sheet. At the same time, any pressure on margins or higher funding needs may limit how much investors are willing to pay for the stock.
• On Simply Wall St's checks, CONMED looks undervalued on 5 of 6 measures, so the broader indicators lean cheap even after the recent rebound in the share price, which has lifted the stock 27.1% year to date.

For investors, the debate is whether the current share price already reflects the risks around CONMED's past performance or still leaves room for a re rating if the fundamentals hold up.

Does CONMED Look Undervalued on Earnings?

The P/E ratio is a useful starting point for CONMED because it links the current share price directly to the earnings that support it. For this stock, the current P/E is about 27.3x, which is very close to the Medical Equipment industry average of around 27.4x. On a simple comparison with the wider sector, CONMED does not look extreme in either direction.

The more tailored check here is the fair P/E ratio of about 32.1x, which reflects what investors might typically pay for CONMED given its profile, margins, size and risks. Compared with that benchmark, the current 27.3x P/E implies the stock trades at a discount to what this model suggests could be reasonable, and also below the peer group average of roughly 32.5x.

Overall, CONMED stock appears undervalued on its P/E ratio compared with both its fair multiple and close peers.

The CONMED Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for CONMED pick up where this valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price on the Community page. Each narrative ties its number to a clear view on how CONMED's growth, profitability and risks could develop, which you can revisit as new results and information emerge.

One of the top community narratives on CONMED: 13% overvalued

"Recent research on Conmed shows a split between investors focused on potential sale value and those focused on execution risks and relative appeal within medtech..."

Do you think there's more to the story for CONMED? Head over to our Community to see what others are saying!

The Bottom Line

CONMED screens as undervalued on market multiples, which suggests the current price already builds in a fair amount of caution. The key question is whether the business can sustain the earnings profile that underpins those valuation checks and avoid new balance sheet or margin setbacks. If earnings quality holds together, the current discount could look appealing. If execution stumbles again, the lower multiple may prove to be protection rather than opportunity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.